AGN-193408 SR
Phase 2Small molecule
AbbVieAGN-193408 SR is one of 11 small molecule programs targeting Ocular Hypertension. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Zolymbus
AbbVieApproved
Travatan
NovartisApproved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Vyzulta
BBausch Health Americas, Inc.
Approved
Reference - LUMIGAN
AAmneal Pharmaceuticals, LLC
Phase 3
Rocklatan
CColorado Ophthalmology Associates PC
Phase 3
AGN-193408 SR
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AGN-193408 SR. EMBL-EBI & Wellcome Sanger Institute.
- [4]